journal
MENU ▼
Read by QxMD icon Read
search

Core Evidence

journal
https://www.readbyqxmd.com/read/27790078/imiglucerase-in-the-management-of-gaucher-disease-type-1-an-evidence-based-review-of-its-place-in-therapy
#1
REVIEW
Christine Serratrice, Sebastian Carballo, Jacques Serratrice, Jérome Stirnemann
INTRODUCTION: Gaucher disease is the first lysosomal disease to benefit from enzyme replacement therapy, thus serving as model for numerous other lysosomal diseases. Alglucerase was the first glucocerebrosidase purified from placental extracts, and this was then replaced by imiglucerase - a Chinese hamster ovary cell-derived glucocerebrosidase. AIM: The aim was to review the evidence underlying the use of imiglucerase in Gaucher disease type 1. EVIDENCE REVIEW: Data from clinical trials and Gaucher Registries were analyzed...
2016: Core Evidence
https://www.readbyqxmd.com/read/27621699/everolimus-in-the-management-of-metastatic-renal-cell-carcinoma-an-evidence-based-review-of-its-place-in-therapy
#2
REVIEW
Sebastiano Buti, Alessandro Leonetti, Alice Dallatomasina, Melissa Bersanelli
INTRODUCTION: Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, and its pathogenesis is strictly related to altered cellular response to hypoxia, in which mTOR signaling pathway is implicated. Everolimus, an mTOR serine/threonine kinase inhibitor, represents a therapeutic option for the treatment of advanced RCC. AIM: The objective of this article is to review the evidence for the treatment of metastatic RCC with everolimus. EVIDENCE REVIEW: Everolimus was approved for second- and third-line therapy in patients with advanced RCC according to the results of a Phase III pivotal trial that demonstrated a benefit in median progression-free survival of ~2 months compared to placebo after failure of previous lines of therapy, of which at least one was an anti-VEGFR tyrosine kinase inhibitor (TKI)...
2016: Core Evidence
https://www.readbyqxmd.com/read/27445644/pirfenidone-in-the-treatment-of-idiopathic-pulmonary-fibrosis-an-evidence-based-review-of-its-place-in-therapy
#3
REVIEW
George A Margaritopoulos, Eirini Vasarmidi, Katerina M Antoniou
The landscape of idiopathic pulmonary fibrosis (IPF) has changed. The significant progress regarding our knowledge on the pathogenesis of the disease together with the experience achieved after a series of negative trials has led to the development of two drugs for the treatment of IPF. Both pirfenidone and nintedanib can slow significantly the rate of disease progression. They are safe with side effects that can be either prevented by close collaboration between health care professionals and patients or treated successfully when they occur, rarely leading to treatment discontinuation...
2016: Core Evidence
https://www.readbyqxmd.com/read/27103882/azilsartan-medoxomil-in-the-management-of-hypertension-an-evidence-based-review-of-its-place-in-therapy
#4
REVIEW
Emiliano Angeloni
BACKGROUND: Azilsartan (AZI) is a relatively new angiotensin receptor blocker available for the treatment of any stage of hypertension, which was eventually given in combination with chlorthalidone (CLT). OBJECTIVE: To review pharmacology and clinical role of AZI monotherapy and AZI/CLT or AZI/amlodipine combination therapies for hypertension management. METHODS: PubMed, Embase, and Cochrane Library were searched using search terms " azilsartan", "chlorthalidone," "pharmacology," "pharmacokinetics," "pharmacodynamics," "pharmacoeconomics," and "cost-effectiveness...
2016: Core Evidence
https://www.readbyqxmd.com/read/26587013/clinical-utility-of-tadalafil-in-the-treatment-of-pulmonary-arterial-hypertension-an-evidence-based-review
#5
REVIEW
Adam M Henrie, James J Nawarskas, Joe R Anderson
Pulmonary arterial hypertension (PAH) is a chronic and disabling condition characterized by an elevated pulmonary vascular resistance and an elevated mean pulmonary arterial pressure. Despite recent improvements in treatment availability, PAH remains challenging to treat, burdensome for patients, and ultimately incurable. Tadalafil is a phos-phodiesterase-5 inhibitor that is administered once daily by mouth for the treatment of PAH. Current treatment guidelines recommend tadalafil as an option for patients with World Health Organization functional class II or III PAH...
2015: Core Evidence
https://www.readbyqxmd.com/read/26346347/nintedanib-evidence-for-its-therapeutic-potential-in-idiopathic-pulmonary-fibrosis
#6
REVIEW
Minoru Inomata, Yasuhiko Nishioka, Arata Azuma
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. The molecular mechanisms involved in the progression of IPF are not fully understood; however, the platelet-derived growth factor (PDGF)/PDGF receptor pathway is thought to play a critical role in fibrogenesis of the lungs. Other growth factors, including fibroblast growth factor and vascular endothelial growth factor, are also thought to contribute to the pathogenesis of pulmonary fibrosis. Nintedanib is an inhibitor of multiple tyrosine kinases, including receptors for PDGF, fibroblast growth factor, and vascular endothelial growth factor...
2015: Core Evidence
https://www.readbyqxmd.com/read/26345982/palonosetron-in-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-an-evidence-based-review-of-safety-efficacy-and-place-in-therapy
#7
REVIEW
Luigi Celio, Monica Niger, Francesca Ricchini, Francesco Agustoni
INTRODUCTION: The second-generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonist palonosetron is effective in the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly and moderately emetogenic chemotherapy (HEC and MEC, respectively). In addition, palonosetron has been the first and, at present, the only 5-HT3 receptor antagonist to have a specific indication for the prevention of delayed CINV associated with MEC. The unique pharmacology of this antagonist is thought to partly explain its improved efficacy against delayed symptoms...
2015: Core Evidence
https://www.readbyqxmd.com/read/26019695/an-evidence-based-review-of-edoxaban-and-its-role-in-stroke-prevention-in-patients-with-nonvalvular-atrial-fibrillation
#8
REVIEW
Tushar Acharya, Prakash Deedwania
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke. As a result, atrial fibrillation patients are risk-stratified using the CHADS2 or CHA2DS2-VASc scoring systems. Those at intermediate-to-high risk have traditionally been treated with therapeutic anticoagulation with warfarin for stroke prevention. Although effective, warfarin use is fraught with multiple concerns, such as a narrow therapeutic window, drug-drug and drug-food interactions, and excessive bleeding...
2015: Core Evidence
https://www.readbyqxmd.com/read/25945081/vilazodone-for-the-treatment-of-major-depressive-disorder-an-evidence-based-review-of-its-place-in-therapy
#9
REVIEW
David J Hellerstein, Joseph Flaxer
INTRODUCTION: It has clearly been demonstrated that depressive disorders constitute a major worldwide public health problem, with massive economic and quality-of-life consequences. Existing pharmacological treatments have limited efficacy, with only about a third of patients achieving remission on any one medication. Delayed onset of action and variable tolerability contribute to this limited efficacy. Vilazodone, introduced in the US in 2011, has been described as the first member of the serotonin partial agonist-reuptake inhibitor (SPARI) class of medications, combining serotonin-reuptake inhibition with 5-HT1A partial agonism...
2015: Core Evidence
https://www.readbyqxmd.com/read/25709561/oritavancin-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-an-evidence-based-review
#10
REVIEW
Joumana Kmeid, Zeina A Kanafani
The emergence of resistance to glycopeptide antibiotics such as vancomycin and teicoplanin among Gram-positive bacteria has spurred the search for second-generation drugs of this class. Oritavancin, a promising novel, second-generation, semisynthetic lipoglycopeptide, is distinguished by two mechanisms of action: inhibition of cell wall synthesis and disruption of the cell membrane. This dual mechanism of action has increased the activity of oritavancin against vancomycin-resistant Gram-positive bacteria compared to other glycopeptides...
2015: Core Evidence
https://www.readbyqxmd.com/read/25657615/dulaglutide-an-evidence-based-review-of-its-potential-in-the-treatment-of-type-2-diabetes
#11
REVIEW
Krystal L Edwards, Molly G Minze
INTRODUCTION: As the prevalence of type 2 diabetes mellitus (T2DM) is anticipated to continue to rise worldwide, so too are the treatment options also continuing to expand. Current guidelines recommend individualized treatment plans which allow for provider choice and diversity of pharmacotherapeutic regimens. The glucagon-like peptide-1 receptor agonist (GLP-1 RA) class is rapidly expanding, with dulaglutide (Trulicity™) as a once-weekly agent recently approved. AIMS: This article examines the evidence currently available on the efficacy and safety of dulaglutide for use in T2DM...
2015: Core Evidence
https://www.readbyqxmd.com/read/25610345/rasburicase-in-the-management-of-tumor-lysis-an-evidence-based-review-of-its-place-in-therapy
#12
REVIEW
Jennifer Dinnel, Bonny L Moore, Brent M Skiver, Prithviraj Bose
Tumor lysis syndrome (TLS) is a potentially life-threatening complication of cancer therapy characterized by two or more of the following laboratory abnormalities: hyperuricemia, hyperkalemia, hypocalcemia, and hyperphosphatemia, with resultant end-organ damage, eg, renal failure, seizures, or cardiac arrhythmias. High-risk patients include those with highly proliferative cancers and/or large tumor burdens, particularly in the setting of highly effective chemotherapy, among other risk factors. Before 2002, antihyperuricemic drug therapy was limited to allopurinol, a xanthine oxidase inhibitor...
2015: Core Evidence
https://www.readbyqxmd.com/read/25565923/sipuleucel-t-in-the-treatment-of-prostate-cancer-an-evidence-based-review-of-its-place-in-therapy
#13
REVIEW
Julie N Graff, Erin D Chamberlain
Metastatic castration-resistant prostate cancer is the lethal form of cancer of the prostate. Five new agents that prolong survival in this group have emerged in the past 5 years, and sipuleucel-T is among them. Sipuleucel-T is the only immunotherapy shown to improve survival in prostate cancer. It is currently indicated in asymptomatic or mildly symptomatic patients, as it has never shown a direct cancer effect. This paper describes the process of creating the sipuleucel-T product from the manufacturing and patient aspects...
2015: Core Evidence
https://www.readbyqxmd.com/read/25285056/luliconazole-for-the-treatment-of-fungal-infections-an-evidence-based-review
#14
REVIEW
Deepshikha Khanna, Subhash Bharti
Luliconazole is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture. In this review, we summarize the in vitro data, animal studies, and clinical trial data relating to the use of topical luliconazole. Preclinical studies have demonstrated excellent activity against dermatophytes. Further, in vitro/in vivo studies have also shown favorable activity against Candida albicans, Malassezia spp...
2014: Core Evidence
https://www.readbyqxmd.com/read/25278817/colistimethate-sodium-for-the-treatment-of-chronic-pulmonary-infection-in-cystic-fibrosis-an-evidence-based-review-of-its-place-in-therapy
#15
REVIEW
Cordula Koerner-Rettberg, Manfred Ballmann
Chronic bacterial respiratory-tract infections are a major driving force in the pathogenesis of cystic fibrosis (CF) lung disease and promote chronic lung-function decline, destruction, and progression to respiratory failure at a premature age. Gram-negative bacteria colonizing the airways in CF are a major problem in CF therapy due to their tendency to develop a high degree of resistance to antibiotic agents over time. Pseudomonas aeruginosa is the dominating bacterial strain infecting the CF lung from early childhood on, and multiresistant strains frequently develop after years of therapy...
2014: Core Evidence
https://www.readbyqxmd.com/read/25114628/regorafenib-an-evidence-based-review-of-its-potential-in-patients-with-advanced-liver-cancer
#16
REVIEW
Sujan Ravi, Ashwani K Singal
Hepatocellular carcinoma (HCC) is the second-most common cause of cancer-related death in the world. In spite of HCC surveillance with repeated imaging, about 50% of patients are diagnosed at an advanced stage and are not amenable to curative treatment options. Sorafenib, a multikinase inhibitor, remains the standard of care for advanced HCC. Over the last 5 years, several other medications have been tested in Phase III trials. However, they have not shown any added benefit over sorafenib. Regorafenib, another multikinase inhibitor, has demonstrated inhibition of a broader range of kinases, along with higher inhibition potential in preclinical models...
2014: Core Evidence
https://www.readbyqxmd.com/read/25093016/brodalumab-an-evidence-based-review-of-its-potential-in-the-treatment-of-moderate-to-severe-psoriasis
#17
REVIEW
Susana Coimbra, Américo Figueiredo, Alice Santos-Silva
Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E...
2014: Core Evidence
https://www.readbyqxmd.com/read/25018685/clinical-utility-of-treprostinil-in-the-treatment-of-pulmonary-arterial-hypertension-an-evidence-based-review
#18
REVIEW
Mitchell S Buckley, Andrew J Berry, Nadine H Kazem, Shardool A Patel, Paul A Librodo
Pulmonary arterial hypertension (PAH) remains a progressive disease without a cure, despite the development of several treatment options over the past several decades. Its management strategy consists of the endothelin receptor antagonists (ambrisentan, bosentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil), and prostacyclin analogs (epoprostenol, treprostinil, iloprost). Treprostinil, a stable prostacyclin analog, displays vasodilatory effects in the pulmonary vasculature, as well as antiplatelet aggregation properties...
2014: Core Evidence
https://www.readbyqxmd.com/read/24790591/development-of-cabozantinib-for-the-treatment-of-prostate-cancer
#19
REVIEW
Ulka N Vaishampayan
Cabozantinib (XL184) is a multitargeted receptor tyrosine kinase with predominantly MET and vascular endothelial growth factor inhibition properties. It is currently approved by the US Food and Drug Administration for the treatment of progressive metastatic medullary thyroid cancer. The agent has a convenient once-daily oral dosing schedule and has demonstrated encouraging activity in metastatic castrate-resistant prostate cancer (CRPC). A Phase I/II trial demonstrated responses in soft tissue, visceral disease, and bone metastases in CRPC...
2014: Core Evidence
https://www.readbyqxmd.com/read/24711777/ocriplasmin-for-symptomatic-vitreomacular-adhesion-an-evidence-based-review-of-its-potential
#20
REVIEW
Su Jeong Song, William E Smiddy
Vitreomacular traction is a multicategory entity that may cause substantial visual loss due to the formation of a macular hole or traction-induced tissue distortion. The advent of optical coherent tomography (OCT) has demonstrated the anatomic features of persistent vitreomacular attachment (VMA) more definitively, including in many asymptomatic or minimally symptomatic patients. The indications for intervention are unclear, since it is not possible to predict which eyes might be likely to develop progressive visual loss...
2014: Core Evidence
journal
journal
41160
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"